These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 19266094)

  • 1. The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.
    Almendro V; Ametller E; García-Recio S; Collazo O; Casas I; Augé JM; Maurel J; Gascón P
    PLoS One; 2009; 4(3):e4728. PubMed ID: 19266094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.
    Ametller E; García-Recio S; Pastor-Arroyo EM; Callejo G; Carbó N; Gascón P; Almendro V
    Cancer Biol Ther; 2011 Jan; 11(1):4-13. PubMed ID: 20980803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
    Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
    Lei G; Liu S; Yang X; He C
    Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
    Moser C; Lang SA; Kainz S; Gaumann A; Fichtner-Feigl S; Koehl GE; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Nov; 6(11):2868-78. PubMed ID: 18025273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
    Griffiths GJ; Koh MY; Brunton VG; Cawthorne C; Reeves NA; Greaves M; Tilby MJ; Pearson DG; Ottley CJ; Workman P; Frame MC; Dive C
    J Biol Chem; 2004 Oct; 279(44):46113-21. PubMed ID: 15326164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
    McDermott U; Longley DB; Galligan L; Allen W; Wilson T; Johnston PG
    Cancer Res; 2005 Oct; 65(19):8951-60. PubMed ID: 16204068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acquisition of anticancer drug resistance is partially associated with cancer stemness in human colon cancer cells.
    El Khoury F; Corcos L; Durand S; Simon B; Le Jossic-Corcos C
    Int J Oncol; 2016 Dec; 49(6):2558-2568. PubMed ID: 27748801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J; McLean EG; Aroori S; Wilson P; McCulla A; Carey PD; Longley DB; Johnston PG
    Clin Cancer Res; 2004 Mar; 10(6):2158-67. PubMed ID: 15041737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL.
    El Fajoui Z; Toscano F; Jacquemin G; Abello J; Scoazec JY; Micheau O; Saurin JC
    Gastroenterology; 2011 Aug; 141(2):663-73. PubMed ID: 21683075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity.
    Micheau O; Solary E; Hammann A; Martin F; Dimanche-Boitrel MT
    J Natl Cancer Inst; 1997 Jun; 89(11):783-9. PubMed ID: 9182976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
    Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.
    Meng RD; Shelton CC; Li YM; Qin LX; Notterman D; Paty PB; Schwartz GK
    Cancer Res; 2009 Jan; 69(2):573-82. PubMed ID: 19147571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells.
    Wang X; Li M; Wang J; Yeung CM; Zhang H; Kung HF; Jiang B; Lin MC
    Biochem Pharmacol; 2006 May; 71(11):1540-50. PubMed ID: 16595125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Her2-Nrf2 axis in induction of oxaliplatin resistance in colon cancer cells.
    Pirpour Tazehkand A; Akbarzadeh M; Velaie K; Sadeghi MR; Samadi N
    Biomed Pharmacother; 2018 Jul; 103():755-766. PubMed ID: 29684854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
    Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
    Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells.
    Arango D; Wilson AJ; Shi Q; Corner GA; Arañes MJ; Nicholas C; Lesser M; Mariadason JM; Augenlicht LH
    Br J Cancer; 2004 Nov; 91(11):1931-46. PubMed ID: 15545975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.